Abstrakt

Przypisy

• 1. Abd El-Rehim D.M., Pinder S.E., Paish C.E., Bell J.A., RampaulR.S., Blamey R.W., Robertson J.F., Nicholson R.I., Ellis I.O.: Expressionand co-expression of the members of the epidermal growth factorreceptor (EGFR) family in invasive breast carcinoma. Br. J. Cancer,2004; 91: 1532-1542
  Google Scholar
• 2. Adamson E.D.: Oncogenes in development. Development, 1987;99: 449-471
  Google Scholar
• 3. Ainsworth R., Bartlett J.M., Going J.J., Mallon E.A., Forsyth A.,Richmond J., Angerson W., Watters A., Dunne B.: IHC for Her2 withCBE356 antibody is a more accurate predictor of Her2 gene amplificationby FISH than HercepTestTM in breast carcinoma. J. Clin.Pathol., 2005; 58: 1086-1090
  Google Scholar
• 4. Andrulis I.L., Bull S.B., Blackstein M.E., Sutherland D., Mak C.,Sidlofsky S., Pritzker K.P., Hartwick R.W., Hanna W., Lickley L., WilkinsonR., Qizilbash A., Ambus U., Lipa M., Weizel H. et al.: Neu/erbB-2 amplification identifies a poor-prognosis group of womenwith node-negative breast cancer. J. Clin. Oncol., 1998; 16: 1340-1349
  Google Scholar
• 5. Baselga J., Carbonell X., Castaneda-Soto N.J., Clemens M., GreenM., Harvey V., Morales S., Barton C., Ghahramani P.: Phase II studyof efficacy, safety, and pharmacokinetics of trastuzumab monotherapyadministered on a 3-weekly schedule. J. Clin. Oncol., 2005; 23:2162-2171
  Google Scholar
• 6. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C.,Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P.,Twaddell T., Henderson I.C., Norton L.: Phase II study of weekly intravenousrecombinant humanized anti-p185HER2 monoclonal antibodyin patients with HER2/neu-overexpressing metastatic breastcancer. J. Clin. Oncol., 1996; 14: 737-744
  Google Scholar
• 7. Berger M.S., Locher G.W., Saurer S., Gullick W.J., Waterfield M.D.,Groner B., Hynes N.E.: Correlation of c-erbB-2 gene amplification andprotein expression in human breast carcinoma with nodal status andnuclear grading. Cancer Res., 1988; 48: 1238-1243
  Google Scholar
• 8. Bieche I., Onody P., Tozlu S., Driouch K., Vidaud M., Lidereau R.:Prognostic value of ERBB family mRNA expression in breast carcinomas.Int. J. Cancer, 2003; 106: 758-765
  Google Scholar
• 9. Bose S., Wang S.I., Terry M.B., Hibshoosh H., Parsons R.: Allelicloss of chromosome 10q23 is associated with tumor progression inbreast carcinomas. Oncogene, 1998; 17: 123-127
  Google Scholar
• 10. Brennan P.J., Kumogai T., Berezov A., Murali R., Greene M.I.:HER2/Neu: mechanisms of dimerization/oligomerization. Oncogene,2000; 19: 6093-6101
  Google Scholar
• 11. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B.,Denney D.W.Jr., Leahy D.J.: Structure of the extracellular region ofHER2 alone and in complex with the herceptin Fab. Nature, 2003;421: 756-760
  Google Scholar
• 12. Chung J.H., Ostrowski M.C., Romigh T., Minaguchi T., Waite K.A.,Eng C.: The ERK1/2 pathway modulates nuclear PTEN-mediated cellcycle arrest by cyclin D1 transcriptional regulation. Hum. Mol. Genet.,2006; 15: 2553-2559
  Google Scholar
• 13. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., FehrenbacherL., Wolter J.M., Paton V., Shak S., Lieberman G., SlamonD.J.: Multinational study of the efficacy and safety of humanizedanti-HER2 monoclonal antibody in women who have HER2-overexpressingmetastatic breast cancer that has progressed after chemotherapyfor metastatic disease. J. Clin. Oncol., 1999; 17: 2639-2648
  Google Scholar
• 14. Crowder R.J., Lombardi D.P., Ellis M.J.: Successful targeting ofErbB2 receptors – is PTEN the key? Cancer Cell, 2004; 6: 103-104
  Google Scholar
• 15. Culouscou J.M., Carlton G.W., Aruffo A.: HER4 receptor activationand phosphorylation of Shc proteins by recombinant heregulin-Fcfusion proteins. J. Biol. Chem., 1995; 270: 12857-12863
  Google Scholar
• 16. Depowski P.L., Rosenthal S.I., Ross J.S.: Loss of expression of thePTEN gene protein product is associated with poor outcome in breastcancer. Mod. Pathol., 2001; 14: 672-676
  Google Scholar
• 17. DiGiovanna M.P., Stern D.F., Edgerton S., Broadwater G., DresslerL.G., Budman D.R., Henderson I.C., Norton L., Liu E.T., MussH.B., Berry D.A., Hayes D.F., Thor A.D.: Influence of activation stateof ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin,and fluorouracil for stage II, node-positive breast cancer:Study 8541 from the Cancer and Leukemia Group B. J. Clin. Oncol.,2008; 26: 2364-2372
  Google Scholar
• 18. DiGiovanna M.P., Stern D.F., Edgerton S.M., Whalen S.G., MooreII D., Thor A.D.: Relationship of epidermal growth factor receptorexpression to ErbB-2 signaling activity and prognosis in breast cancerpatients. J. Clin. Oncol., 2005; 23: 1152-1160
  Google Scholar
• 19. Frogne T., Laenkholm A.V., Lyng M.B., Henriksen K.L., LykkesfeldtA.E.: Determination of HER2 phosphorylation at tyrosine1221/1222 improves prediction of poor survival for breast cancerpatients with hormone receptor-positive tumors. Breast CancerRes., 2009; 11: R11
  Google Scholar
• 20. Fujita T., Doihara H., Kawasaki K., Takabatake D., Takahashi H.,Washio K., Tsukuda K., Ogasawara Y., Shimizu N.: PTEN activity couldbe a predictive marker of trastuzumab efficacy in the treatment ofErbB2-overexpressing breast cancer. Br. J. Cancer, 2006; 94: 247-252
  Google Scholar
• 21. Gasparini G., Gullick W.J., Bevilacqua P., Sainsbury J.R., Meli S.,Boracchi P., Testolin A., La Malfa G., Pozza F.: Human breast cancer:prognostic significance of the c-erbB-2 oncoprotein compared withepidermal growth factor receptor, DNA ploidy and conventional pathologicfeatures. J. Clin. Oncol., 1992; 10: 686-695
  Google Scholar
• 22. Grushko T.A., Filiaci V.L., Mundt A.J., Ridderstråle K., OlopadeO.I., Fleming G.F.: An exploratory analysis of HER-2 amplification andoverexpression in advanced endometrial carcinoma: a gynecologiconcology group study. Gynecol. Oncol., 2008; 108: 3-9
  Google Scholar
• 23. Hobert J.A., Eng C.: PTEN hamartoma tumor syndrome: an overview.Genet. Med., 2009; 11: 687-694
  Google Scholar
• 24. Hsieh A.C., Moasser M.M.: Targeting HER proteins in cancertherapy and the role of the non-target HER3. Br. J. Cancer, 2007;97: 453-457
  Google Scholar
• 25. Huang X., Gao L., Wang S., McManaman J.L., Thor A.D., Yang X.,Esteva F.J., Liu B.: Heterotrimerization of the growth factor receptorserbB2, erbB3, and insulin-like growth factor-I receptor in breastcancer cells resistant to herceptin. Cancer Res., 2010; 70: 1204-1214
  Google Scholar
• 26. Hudelist G., Kostler W.J., Attems J., Czerwenka K., Müller R.,Manavi M., Steger G.G., Kubista E., Zielinski C.C., Singer C.F.: Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevanceof ligand-independent activation mechanisms and impactupon the efficacy of trastuzumab-based treatment. Br. J. Cancer,2003; 89: 983-991
  Google Scholar
• 27. Hudelist G., Köstler W.J., Czerwenka K., Kubista E., Attems J., MüllerR., Gschwantler-Kaulich D., Manavi M., Huber I., Hoschützky H.,Zielinski C.C., Singer C.F.: Her-2/neu and EGFR tyrosine kinase activationpredict the efficacy of trastuzumab-based therapy in patientswith metastatic breast cancer. Int. J. Cancer, 2006; 118: 1126-1134
  Google Scholar
• 28. Knowlden J.M., Gee J.M., Seery L.T., Farrow L., Gullick W.J., EllisI.O., Blamey R.W., Robertson J.F., Nicholson R.I.: C-erbB3 and c-erbB4expression is a feature of the endocrine responsive phenotype inclinical breast cancer. Oncogene, 1998; 17: 1949-1957
  Google Scholar
• 29. Koutras A.K., Evans T.R.: The epidermal growth factor receptorfamily in breast cancer. Onco. Targets. Ther., 2008; 1: 5-19
  Google Scholar
• 30. Lee Y., Cho S., Seo J.H., Shin B.K., Kim H.K., Kim I., Kim A.: Correlatedexpression of erbB-3 with hormone receptor expressionand favorable clinical outcome in invasive ductal carcinomas of thebreast. Am. J. Clin. Pathol., 2007; 128: 1041-1049
  Google Scholar
• 31. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., HoeflichK.P., Sliwkowski M.X., Stern H.M.: A central role for HER3 inHER2-amplified breast cancer: implications for targeted therapy.Cancer Res., 2008; 68: 5878-5887
  Google Scholar
• 32. Lemoine N.R., Jain S., Silvestre F., Lopes C., Hughes C.M., McLellandE., Gullick W.J., Filipe M.I.: Amplification and overexpression ofthe EGF receptor and c-erbB-2 proto-oncogenes in human stomachcancer. Br. J. Cancer, 1991; 64: 79-83
  Google Scholar
• 33. Lenferink A.E., Pinkas-Kramarski R., van de Poll M.L., van VugtM.J., Klapper L.N., Tzahar E., Waterman H., Sela M., van Zoelen E.J.,Yarden Y.: Differential endocytic routing of homo- and hetero-dimericErbB tyrosine kinases confers signaling superiority to receptorheterodimers. EMBO J., 1998; 17: 3385-3397
  Google Scholar
• 34. Lu Y., Yu Q., Liu J.H., Zhang J., Wang H., Koul D., McMurray J.S.,Fang X., Yung W.K., Siminovitch K.A., Mills G.B.: Src family protein-tyrosinekinases alter the function of PTEN to regulate phosphatidylinositol3-kinase/AKT cascades. J. Biol. Chem., 2003; 278:40057-40066
  Google Scholar
• 35. McCann A.H., Dervan P.A., O’Regan M., Codd M.B., Gullick W.J.,Tobin B.M., Carney D.N.: Prognostic significance of c-erbB-2 and estrogenreceptor status in human breast cancer. Cancer Res., 1991;51: 3296-3303
  Google Scholar
• 36. Mukohara T.: Mechanisms of resistance to anti-human epidermalgrowth factor receptor 2 agents in breast cancer. Cancer Sci.,2011; 102: 1-8
  Google Scholar
• 37. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., KlosK.S., Li P., Monia B.P., Nguyen N.T., Hortobagyi G.N., Hung M.C., YuD.: PTEN activation contributes to tumor inhibition by trastuzumab,and loss of PTEN predicts trastuzumab resistance in patients. CancerCell, 2004; 6: 117-127
  Google Scholar
• 38. Naidu R., Yadav M., Nair S., Kutty M.K.: Expression of c-erbB3protein in primary breast carcinoma. Br. J. Cancer, 1998; 78: 1385-1390
  Google Scholar
• 39. O’Brien N.A., Browne B.C., Chow L., Wang Y., Ginther C., ArboledaJ., Duffy M.J., Crown J., O’Donovan N., Slamon D.J.: Activatedphosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumabbut not lapatinib. Mol. Cancer Ther., 2010; 9: 1489-1502
  Google Scholar
• 40. Paik S., Hazan R., Fisher E.R., Sass R.E., Fisher B., Redmond C.,Schlessinger J., Lippman M.E., King C.R.: Pathologic findings fromthe national surgical adjuvant breast and bowel project: prognosticsignificance of erbB-2 protein overexpression in primary breast cancer.J. Clin. Oncol., 1990; 8: 103-112
  Google Scholar
• 41. Panigrahi A.R., Pinder S.E., Chan S.Y., Paish E.C., Robertson J.F.,Ellis I.O.: The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with otherprognostic factors and with outcome. J. Pathol., 2004; 204: 93-100
  Google Scholar
• 42. Paterson M.C., Dietrich K.D., Danyluk J., Paterson A.H., Lees A.W.,Jamil N., Hanson J., Jenkins H., Krause B.E., McBlain W.A.: Correlationbetween c-erbB-2 amplification and risk of recurrent disease in node-negativebreast cancer. Cancer Res., 1991; 51: 556-567
  Google Scholar
• 43. Pawlowski V., Revillion F., Hebbar M., Hornez L., Peyrat J.P.:Prognostic value of the type I growth factor receptors in a large seriesof human primary breast cancers quantified with a real-timereverse transcription-polymerase chain reaction assay. Clin. CancerRes., 2000; 6: 4217-4225
  Google Scholar
• 44. Pedersen K., Angelini P.D., Laos S., Bach-Faig A., CunninghamM.P., Ferrer-Ramón C., Luque-García A., García-Castillo J., Parra-PalauJ.L., Scaltriti M., Ramón y Cajal S., Baselga J., Arribas J.: A naturallyoccurring HER2 carboxy-terminal fragment promotes mammarytumor growth and metastasis. Mol. Cell. Biol., 2009; 12: 3319-3331
  Google Scholar
• 45. Perez E.A., Romond E.H., Suman V.J., Jeong J.H., Davidson N.E.,Geyer C.E. Jr., Martino S., Mamounas E.P., Kaufman P.A., Wolmark N.:Four-year follow-up of trastuzumab plus adjuvant chemotherapy foroperable human epidermal growth factor receptor 2-positive breastcancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J.Clin. Oncol., 2011; 29: 3366-3373
  Google Scholar
• 46. Perez-Tenorio G., Alkhori L., Olsson B., Waltersson M.A., NordenskjöldB., Rutqvist L.E., Skoog L., Stål O.: PIK3CA mutations and PTENloss correlate with similar prognostic factors and are not mutuallyexclusive in breast cancer. Clin. Cancer Res., 2007; 13: 3577-3584
  Google Scholar
• 47. Perren A., Weng L.P., Boag A.H., Ziebold U., Thakore K., Dahia P.L.,Komminoth P., Lees J.A., Mulligan L.M., Mutter G.L., Eng C.: Immunohistochemicalevidence of loss of PTEN expression in primary ductaladenocarcinomas of the breast. Am. J. Pathol., 1999; 155: 1253-1260
  Google Scholar
• 48. Piekarski J.H., Biernat W.: Clinical significance of CK5/6 andPTEN protein expression in patients with bilateral breast carcinoma.Histopathology, 2006; 49: 248-255
  Google Scholar
• 49. Potemski P., Płuciennik E., Bednarek A.K., Kusińska R., Pasz-WalczakG., Jesionek-Kupnicka D., Watala C., Kordek R.: A comparativeassessment of HER2 status in operable breast cancer by real-timeRT-PCR and by immunohistochemistry. Med. Sci. Monit., 2006; 12:MT57-MT61
  Google Scholar
• 50. Ross J.S., Slodkowska E.A., Symmans W.F., Pusztai L., RavdinP.M., Hortobagyi G.N.: The HER-2 receptor and breast cancer: tenyears of targeted anti–HER-2 therapy and personalized medicine.Oncologist, 2009; 14: 320-368
  Google Scholar
• 51. Sassen A., Rochon J., Wild P., Hartmann A., Hofstaedter F.,Schwarz S., Brockhoff G.: Cytogenetic analysis of HER1/EGFR, HER2,HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res.,2008; 10: R2
  Google Scholar
• 52. Scaltriti M., Rojo F., Ocańa A., Anido J., Guzman M., Cortes J., DiCosimo S., Matias-Guiu X., Ramon y Cajal S., Arribas J., Baselga J.:Expression of p95HER2, a truncated form of the HER2 receptor, andresponse to anti – HER2 therapies in breast cancer. J. Natl. CancerInst., 2007; 99: 628-638
  Google Scholar
• 53. Schechter A.L., Stern D.F., Vaidyanathan L., Decker S.J., DrebinJ.A., Greene M.I., Weinberg R.A.: The neu oncogene: an erb-B-relatedgene encoding a 185,000-Mr tumor antigen. Nature, 1984; 312: 513-516
  Google Scholar
• 54. Shi W., Zhang X., Pintilie M., Ma N., Miller N., Banerjee D., TsaoM.S., Mak T., Fyles A., Liu F.F.: Dysregulated PTEN-PKB and negativereceptor status in human breast cancer. Int. J. Cancer, 2003;104: 195-203
  Google Scholar
• 55. Shoman N., Klassen S., McFadden A., Bickis M.G., Torlakovic E.,Chibbar R.: Reduced PTEN expression predicts relapse in patientswith breast carcinoma treated by tamoxifen. Mod. Pathol., 2005;18: 250-259
  Google Scholar
• 56. Siegel P.M., Ryan E.D., Cardiff R.D., Muller W.J.: Elevated expressionof activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications forhuman breast cancer. EMBO J., 1999; 18: 2149-2164
  Google Scholar
• 57. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuireW.L.: Human breast cancer: correlation of relapse and survival withamplification of the HER-2/neu oncogene. Science, 1987; 235: 177-182
  Google Scholar
• 58. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., KeithD.E., Levin W.J., Stuart S.G., Udove J., Ullrich A.: Studies of theHER-2/neu proto-oncogene in human breast and ovarian cancer.Science, 1989; 244: 707-712
  Google Scholar
• 59. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., BajamondeA., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J.,Norton L.: Use of chemotherapy plus monoclonal antibody againstHER2 for metastatic breast cancer that overexpresses HER2. N. Engl.J. Med., 2001; 344: 783-792
  Google Scholar
• 60. Smith B.L., Chin D., Maltzman W., Crosby K., Hortobagyi G.N.,Bacus S.S.: The efficacy of herceptin therapies is influenced by theexpression of other erbB receptors, their ligands and the activationof downstream signalling proteins. Br. J. Cancer, 2004; 91: 1190-1194
  Google Scholar
• 61. Somerville J.E., Clarke L.A., Biggart J.D.: c-erbB-2 overexpressionand histological type of in situ and invasive breast carcinoma. J. Clin.Pathol., 1992; 45: 16-20
  Google Scholar
• 62. Spector N.L., Blackwell K.L.: Understanding the mechanismsbehind trastuzumab therapy for human epidermal growth factorreceptor 2–positive breast cancer. J. Clin. Oncol., 2009; 27: 5838-5847
  Google Scholar
• 63. Spielmann M., Roché H., Delozier T., Canon J.L., Romieu G., BourgeoisH., Extra J.M., Serin D., Kerbrat P., Machiels J.P., Lortholary A.,Orfeuvre H., Campone M., Hardy-Bessard A.C., Coudert B. et al.: Trastuzumabfor patients with axillary-node-positive breast cancer: resultsof the FNCLCC-PACS 04 trial. J. Clin. Oncol., 2009; 27: 6129-6134
  Google Scholar
• 64. Thor A.D., Liu S., Edgerton S., Moore D. 2nd, Kasowitz K.M., BenzC.C., Stern D.F., DiGiovanna M.P.: Activation (tyrosine phosphorylation)of ErbB-2 (HER-2/neu): a study of incidence and correlationwith outcome in breast cancer. J. Clin. Oncol., 2000; 18: 3230-3239
  Google Scholar
• 65. Tiwari R.K., Borgen P.I., Wong G.Y., Cordon-Cardo C, OsborneM.P.: HER-2/neu amplification and overexpression in primary humanbreast cancer is associated with early metastasis. AnticancerRes., 1992; 12: 419-425
  Google Scholar
• 66. Travis A, Pinder SE, Robertson J.F., Bell J.A., Wencyk P., Gullick W.J.,Nicholson R.I., Poller D.N., Blamey R.W., Elston C.W., Ellis I.O.: C-erbB-3in human breast carcinoma: expression and relation to prognosisand established prognostic indicators. Br. J. Cancer, 1996; 74: 229-233
  Google Scholar
• 67. Valabrega G., Montemurro F., Aglietta M.: Trastuzumab: mechanismof action, resistance and future perspectives in HER2-overexpressingbreast cancer. Ann. Oncol., 2007; 18: 977-984
  Google Scholar
• 68. Valabrega G., Montemurro F., Sarotto I., Petrelli A., Rubini P.,Tacchetti C., Aglietta M., Comoglio P.M., Giordano S.: TGFα expressionimpairs trastuzumab-induced HER2 downregulation. Oncogene,2005; 24: 3002-3010
  Google Scholar
• 69. van Dam P.A., Vergote I.B., Lowe D.G., Watson J.V., van DammeP., van der Auwera J.C., Shepherd J.H.: Expression of c-erbB-2, c-myc,and c-ras oncoproteins, insulin-like growth factor receptor I andepidermal growth factor receptor in ovarian carcinoma. J. Clin. Pathol.,1994; 47: 914-919
  Google Scholar
• 70. Voduc K.D., Cheang M.C., Tyldesley S., Gelmon K., Nielsen T.O.,Kennecke H.: Breast cancer subtypes and the risk of local and regionalrelapse. J. Clin. Oncol., 2010; 28: 1684-1691
  Google Scholar
• 71. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N.,Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., BurchmoreM., Shak S., Stewart S.J., Press M.: Efficacy and safety of trastuzumabas a single agent in first-line treatment of HER2-overexpressing metastaticbreast cancer. J. Clin. Oncol., 2002; 20: 719-726
  Google Scholar
• 72. Waterman H., Alroy I., Strano S., Seger R., Yarden Y.: The c-terminusof the kinase-defective neuregulin receptor ErbB-3 confersmitogenic superiority and dictates endocytic routing. EMBO J., 1999;18: 3348-3358
  Google Scholar
• 73. Xia W., Husain I., Liu L., Bacus S., Saini S., Spohn J., Pry K., WestlundR., Stein S.H., Spector N.L.: Lapatinib antitumor activity isnot dependent upon phosphatase and tensin homologue deletedon chromosome 10 in ErbB2-overexpressing breast cancers. CancerRes., 2007; 67: 1170-1175
  Google Scholar
• 74. Yonemori K., Tsuta K., Shimizu C., Hatanaka Y., Hirakawa A.,Ono M., Kouno T., Katsumata N., Ando M., Tamura K., Hasegawa T.,Kinoshita T., Fujiwara Y.: Immunohistochemical expression of HER1,HER3, and HER4 in HER2-positive breast cancer patients treatedwith trastuzumab-containing neoadjuvant chemotherapy. J. Surg.Oncol., 2010; 101: 222-227
  Google Scholar
• 75. Zhao J., Wu R., Au A., Marquez A., Yu Y., Shi Z.: Determinationof HER2 gene amplification by chromogenic in situ hybridization(CISH) in archival breast carcinoma. Mod. Pathol., 2002; 15: 657-665
  Google Scholar

Pełna treść artykułu